logo
ProjectEnded

Developing a Chlamydia Trachomatis vaccine

Sector: Hospital • Location: Denmark, United Kingdom, France

Source: EU Funding & Tenders Portal

The TRACVAC Consortium will eliminate the global problem of blinding trachoma through the development of a vaccine. Our strategy of the project will eliminate two important bottlenecks for the development of a trachoma vaccine 1) The lack of neutralizing antibody responses to vaccine preparations based on MOMP 2) The challenge of inducing vaccine promoted sustained local ocular IgA. TRACVAC has tw

Status
Closed
Sector
Hospital, Government
Location
Denmark, United Kingdom, France
Updated
22 Jul 2026
Source
EU Funding & Tenders Portal

ConstructChat

Ask ConstructChat about Developing a Chlamydia Trachomatis vaccine

Pick a question to edit it, or write your own.

First answer free · no account

I am a

Project Information FAQ

Project Information

4 Q
The project “Developing a Chlamydia Trachomatis vaccine” is an infrastructure initiative in the Hospital sector, located in Denmark, United Kingdom, France. Taiyo aggregates data on it from EU Funding & Tenders Portal.

Participants

Sponsoring Agency

Status

Original status

ended

Taiyo status

Closed

Taiyo last update

2026-07-22

Contact

Not available for this record.

Description

Description

The TRACVAC Consortium will eliminate the global problem of blinding trachoma through the development of a vaccine. Our strategy of the project will eliminate two important bottlenecks for the development of a trachoma vaccine 1) The lack of neutralizing antibody responses to vaccine preparations based on MOMP 2) The challenge of inducing vaccine promoted sustained local ocular IgA. TRACVAC has two main objectives. The first main objective is to generate a vaccine that protect against the bacterial strains causing ocular Chlamydia trachomatis infections. To accomplish this we first select naturally protected individuals from high endemic regions and identify all neutralizing epitopes from the major outer membrane antigen (MOMP) of Chlamydia trachomatis through the unique combination of the B cell cloning and high density array technology. The epitopes will be produced as vaccines through the use of the immuno-repeat technology that is known to increase the quality and quantity of the vaccine promoted response. The second main objective is to develop an immunization protocol for optimal ocular mucosal immunity. To do this we will establish an ocular non-human primate (NHP) challenge model and use this to test different prime boost vaccination strategies for ocular responses and protection against challenge. We will subsequently test the best strategy in a clinical phase I evaluation of a trachoma vaccine based on a immuno-repeat construct targeting serovar B. This will provide early human proof of concept both for the immuno-repeat technology and the prime boost strategy for ocular IgA. In summary, TRACVAC will deliver a final vaccine candidate targeting the main ocular serovars and a vaccine protocol ready to enter a clinical phase I trial. TRACVAC is highly relevant for the topic (Vaccine development for malaria and/or neglected infectious diseases), as the aim is to accelerate vaccine development against the neglected infectious disease Trachoma.

Location

Country

Denmark, United Kingdom, France

Source

Source

EU Funding & Tenders Portal

URL

More Details

Record type

Project

Sector

Hospital, Government

Article published date

2026-01-15

More on this project

Research

Free account

View all details

You are reading the public part. A free account opens the rest:

  • Every detail on this project
  • News and media coverage
  • Technical research
View all details

Free account · no card · lands you back on this project